Iterum Therapeutics (NASDAQ: ITRM) is one of 546 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Iterum Therapeutics to similar businesses based on the strength of its risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.
This is a breakdown of recent recommendations for Iterum Therapeutics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Iterum Therapeutics Competitors||4499||12939||27592||991||2.54|
Valuation and Earnings
This table compares Iterum Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Iterum Therapeutics||$870,000.00||-$77.06 million||-1.20|
|Iterum Therapeutics Competitors||$2.17 billion||$229.91 million||-3.77|
Iterum Therapeutics’ rivals have higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
45.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.8% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Iterum Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Iterum Therapeutics Competitors||-1,776.08%||-105.48%||-28.48%|
Iterum Therapeutics beats its rivals on 7 of the 12 factors compared.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.